JBC INTERFERin siRNA transfection reagent

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M107373200 on September 10, 2001

J. Biol. Chem., Vol. 276, Issue 47, 44069-44077, November 23, 2001
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/47/44069    most recent
M107373200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bouchier-Hayes, L.
Right arrow Articles by Martin, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bouchier-Hayes, L.
Right arrow Articles by Martin, S. J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

CARDINAL, a Novel Caspase Recruitment Domain Protein, Is an Inhibitor of Multiple NF-kappa B Activation Pathways*

Lisa Bouchier-HayesDagger §, Helen ConroyDagger , Helen EganDagger , Colin AdrainDagger , Emma M. CreaghDagger , Marion MacFarlane, and Seamus J. MartinDagger ||

From the Dagger  Molecular Cell Biology Laboratory, Department of Genetics, Smurfit Institute, Trinity College, Dublin 2, Ireland and the  Medical Research Council Toxicology Unit, University of Leicester, Leicester LE19HN, United Kingdom

Received for publication, August 2, 2001, and in revised form, September 6, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Proteins possessing the caspase recruitment domain (CARD) motif have been implicated in pathways leading to activation of caspases or NF-kappa B in the context of apoptosis or inflammation, respectively. Here we report the identification of a novel protein, CARDINAL, that contains a CARD motif and also exhibits a high degree of homology to the C terminus of DEFCAP/NAC, a recently described member of the Apaf-1/Nod-1 family. In contrast with the majority of CARD proteins described to date, CARDINAL failed to promote apoptosis or NF-kappa B activation. Rather, CARDINAL potently suppressed NF-kappa B activation associated with overexpression of TRAIL-R1, TRAIL-R2, RIP, RICK, Bcl10, and TRADD, or through ligand-induced stimulation of the interleukin-1 or tumor necrosis factor receptors. Co-immunoprecipitation experiments revealed that CARDINAL interacts with the regulatory subunit of the Ikappa B kinase (IKK) complex, IKKgamma (NEMO), providing a molecular basis for CARDINAL function. Thus, CARDINAL is a novel regulator of NF-kappa B activation in the context of pro-inflammatory signals.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The caspase recruitment domain (CARD)1 is a protein-protein interaction motif, comprising a bundle of six alpha -helices, that was first identified in caspases and their associated adaptor molecules (1). Caspases, cysteine aspartic acid-specific proteases, play a key coordinating role in apoptosis by targeting a subset of cellular proteins for limited proteolysis (2-6).

Caspases that participate in apoptosis appear to be organized into hierarchical cascades, with those containing CARD motifs (or the related death effector domain (DED) motif) within their pro-domain regions occupying positions at the apex of caspase activation cascades (3, 5, 7-9). Activation of apical (CARD- or DED-containing) caspases appears to be achieved through aggregation of the latter via interactions between adaptor molecules that contain similar CARD or DED motifs (5, 8, 10). This strategy serves to increase the local concentration of apical caspases and allow processing of adjacent caspase molecules in trans, a process that has been termed the "induced-proximity model" (10).

The CARD motif does not appear to be restricted to caspases and their adaptor proteins, however. Recently, several CARD-containing proteins have been identified (Bcl10, CARD4/Nod1, Nod2, CARD10, CARD11, CARD14), the function of which appears to be directed primarily toward activation of the NF-kappa B transcription factor, rather than caspases (11-19). The prototypical member of this family, Bcl10 (cE10, CIPER, CLAP, CARMEN), has recently been found to be essential for NF-kappa B activation in the context of ligation of the T or B cell receptors for antigen (20). The viral Bcl10 homologue, vCLAP (vE10), is also a potent activator of NF-kappa B and has been shown to interact with the regulatory subunit of the Ikappa B kinase complex, IKKgamma (21). Cellular Bcl10 may also drive NF-kappa B activation via recruitment of IKKgamma , although this remains to be demonstrated.

Several other CARD family proteins have been described that also appear to drive NF-kappa B activation through association with Bcl10 (16, 18, 19). Thus, Bcl10 appears to be an important convergence point for CARD-containing proteins that regulate NF-kappa B activation (see Ref. 22 for a recent review). In the latter cases, CARD:CARD interactions between Bcl10 and its binding partners may facilitate activation of the IKK complex through recruitment of IKKgamma , followed by the IKKalpha and IKKbeta subunits.

More recently, CARD-containing homologues of Apaf-1 (CARD4/Nod1, Nod2) have also been shown to promote NF-kappa B activation through recruitment of the CARD-containing kinase RICK (CARDIAK/RIP-2; Refs. 17 and 23). Moreover, RICK has also been shown to interact with IKKgamma providing a means whereby recruitment of RICK may result in NF-kappa B activation through downstream activation of the IKK complex (23).

Thus, CARD-containing proteins occur repeatedly in stress response pathways that lead to activation of either caspases or NF-kappa B. Activation of the latter molecules results in either apoptosis or transcription of pro-inflammatory genes, responses that are consistent with the preservation of the integrity of multicellular organisms. Here, we describe a novel CARD-containing protein, CARDINAL, which does not appear to be involved in activation of either caspases or NF-kappa B. Instead, CARDINAL was found to inhibit divergent NF-kappa B activation signals and to interact with the regulatory subunit of the Ikappa B kinase complex, IKKgamma /NEMO. Thus, CARDINAL may play a role in setting a threshold for NF-kappa B activation, or in limiting the duration of the NF-kappa B response in the context of pro-inflammatory signals.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Plasmids-- All plasmid constructs were generated using standard polymerase chain reaction procedures with primers designed to incorporate appropriate restriction enzyme sites. Polymerase chain reaction products were then digested and cloned into pcDNA3 (Invitrogen), pEGFP-C3 (CLONTECH), or pGEX4TK2 (Amersham Pharmacia Biotech), as indicated in the text. Plasmids were sequenced on an ABI 310 automated sequencer using ABI PRISM dye terminator cycle sequencing kits (PerkinElmer Life Sciences), according to the manufacturer's instructions.

Antibody Generation and Affinity Purification-- A polyclonal anti-CARDINAL antibody was generated by repeated immunization of rabbits with a GST-CARDINAL fusion protein (amino acids 321-431). Antiserum was purified by running over an Affi-Gel (Bio-Rad) affinity column containing the immobilized GST-CARDINAL-(321-431) fusion protein, followed by elution of bound antibody with 100 mM glycine, pH 2.8.

Western Blot Analysis of CARDINAL Expression on Human Tissues and Human Tumor Cell Lines-- Total protein lysates (100 µg/lane) prepared from a range of normal human tissues (CLONTECH) were electrophoresed on 12% polyacrylamide gels under standard SDS-polyacrylamide gel electrophoresis conditions. Total protein lysates were also prepared from a panel of human tumor cell lines by lysing cells at 107/ml in SDS-polyacrylamide gel electrophoresis sample buffer, followed by electrophoresis of samples (~50 µg/lane) on 12% polyacrylamide gels. Proteins were then transferred onto 0.45-µm nitrocellulose membrane and were probed for CARDINAL or actin expression using specific antibodies.

Luciferase Reporter Assays-- Typically, 2 × 105 HEK 293T cells were transfected with appropriate plasmid combinations using the standard calcium phosphate precipitation method. For NF-kappa B reporter assays, cells were transfected with 100 ng of pGL35Xkappa B-luc, 50 ng of pCMVbeta gal, and amounts of the relevant expression plasmids as described in the figure legends. Total plasmid amounts per well were made equal using pcDNA3 empty vector. The p53 reporter assays were set up in the same way using 100 ng of p53-luciferase reporter plasmid (Stratagene) and 50 ng of pCMVbeta Gal. In some experiments, because of the pro-apoptotic effects associated with some NF-kappa B-inducing molecules (RIP, TRADD, TRAIL-R1, etc.), z-VAD-fmk (5 µM) was added to all wells to minimize loss of cells during the experiment.

24-48 h after transfection, medium was removed from the transfected cells which were then washed with PBS, pH 7.2. Cells were lysed by addition of 150 µl of PBS, followed by an equal volume of luciferase reporter/lysis reagent (luciferase constant light signal reporter gene assay kit; Roche Molecular Biochemicals). The light emitted from triplicate 50-µl aliquots of cell lysates was then measured in black 96-well plates by luminometry. Transfection efficiencies were normalized by measuring beta -galactosidase activities, as follows. Briefly, 50 µl of cell lysate was incubated with 0.66 mg/ml O-nitrophenyl beta -D-galactopyranoside in 1 ml of Z buffer (60 mM Na2HPO4, 40 mM NaH2PO4, 10 mM KCl, 1 mM MgSO4, pH 7) at 37 °C until a color change developed (typically 30 min). The reaction was stopped by addition of 300 µl of 1 M Na2CO3 followed by measurement of beta -galactosidase activity at A420.

Transient Transfection and Co-immunoprecipitation Assays-- Cells (HEK293T) were seeded at a density of 2 × 106 cells/10-cm plate the day before transfection. Cells were transfected with 5-10 µg of appropriate plasmids according to the established calcium phosphate precipitation method, and DNA complexes were typically allowed to remain on cells until harvesting. Cell lysates were made 24-48 h after transfection by resuspending cells in 800 µl of IP lysis buffer (50 mM Tris-Cl, pH 8.0, 150 mM NaCl, 1% Nonidet P-40) containing 100 µM phenylmethylsulfonyl fluoride, 10 µg/ml leupeptin, and 1 µg/ml aprotinin. Following centrifugation, clarified lysates were subjected to immunoprecipitation using 1 µg of the appropriate antibody and 30 µl of agarose-coupled protein A/G (Santa Cruz). Samples were incubated with rotation for 3-6 h at 4 °C, and complexes were washed three to four times in IP lysis buffer containing 0.1% Nonidet P-40. Immunoprecipitates were then analyzed by immunoblotting using appropriate primary and secondary antibodies.

Subcellular Localization-- MCF-7 cells were plated on eight-well chamber slides at a density of 1 × 105 cells/well. The following day, cells were transfected by lipofection using Fugene-6 transfection reagent (Roche Molecular Biochemicals), according to the manufacturer's instructions. Typically, 200 ng of pEGFP-C3-based plasmids encoding GFP or GFP-CARDINAL and its derivatives were transfected per treatment. Approximately 18 h after transfection, cells were stained with Mitotracker red CMXRos (100 nM) for 15 min at 37 °C before fixation in 3.8% formaldehyde in PBS, pH 7.2, for 20 min at room temperature. Cells were then rinsed in PBS, and nuclei were stained with Hoechst 33258 (0.25 g/ml) for 20 min before mounting onto glass coverslips using Vectashield (Vector Laboratories). Optical sections were taken using argon-krypton, UV lasers, and a Leica TCS-4D confocal imaging system.

Apoptosis Assays-- MCF-7 cells were plated at a density of 105 cells/well in six-well plates and transfected the following day with Fugene-6 (2 µl/well). Typically, 800 ng of pcDNA3-based plasmids were transfected along with 50 ng of pCMVbeta gal reporter plasmid (CLONTECH). Cells were washed briefly in serum-free medium 6 h after transfection, and medium was replaced. 24-48 h after transfection, cells were fixed and stained for beta -galactosidase expression as described previously (24). A minimum of 300 blue (transfected) cells/well were assessed for features of apoptosis using standard criteria.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Identification of CARDINAL-- To identify novel CARD-containing proteins, we searched the public expressed sequence tag data bases for clones encoding CARD motifs using the N-terminal prodomain of human caspase-1 (amino acids 1-119) as the query sequence. This search identified a predicted protein encoded by expressed sequence tag clone KIAA0955 (GenBankTM accession no. BAA76799) in the KDRI brain genomic data base, with significant homology to the CARD of caspase-1 within its C terminus. Sequence analysis of this clone revealed an open reading frame that encoded a predicted protein of 431 amino acids (Fig. 1, A and B). BLASTP searches with the predicted protein sequence encoded by this clone revealed significant homology with the CARD domains of several other CARD proteins (Fig. 1C). Furthermore, CARDINAL also exhibited a high degree of homology with the C terminus of the recently described Apaf-1/Nod-1 family member DEFCAP/NAC (Fig. 1D). We have designated this protein CARDINAL, for CARD inhibitor of NF-kappa B-activating ligands (see below).


View larger version (75K):
[in this window]
[in a new window]
 
Fig. 1.   Sequence analysis of CARDINAL and alignment with proteins possessing similar motifs. A, the CARDINAL open reading frame encodes a predicted protein of 431 amino acids. The region encompassing the CARD motif (amino acids 347-431) is underlined. B, schematic representation of the domain structure of human CARDINAL. Numbers represent amino acid positions. C, alignment of the CARD region of CARDINAL (amino acids 341-431) with that of the CARD-containing proteins caspase-1, ASC, caspase-2, CARD4/Nod1, RAIDD, ICEBERG, NAC/DEFCAP. Amino acid positions are indicated to the left of the alignment. D, alignment of CARDINAL with DEFCAP/NACbeta . Amino acids identical to the consensus are shaded black; conservative substitutions are boxed.

Tissue Expression of CARDINAL-- To explore the tissue distribution of CARDINAL, we generated a polyclonal antibody by immunizing rabbits with a GST-CARDINAL (amino acids 321-431) fusion protein. This antibody specifically recognized CARDINAL migrating as a single band of ~50 kDa, which is close to the predicted molecular mass of 49 kDa (Fig. 2A). Western blot analysis using affinity-purified anti-CARDINAL antibody revealed that CARDINAL was expressed in several normal human tissues, including; heart, kidney, liver, lung, ovary, placenta, and testis (Fig. 2B). The highest levels of CARDINAL expression were found in lung, ovary, testis, and placenta with low or absent expression in brain, skeletal muscle, and spleen. Western blot analysis of CARDINAL expression in a panel of transformed human cell lines revealed a high level of expression in the MCF-7 breast carcinoma cell line, with intermediate levels of expression in the monocytic THP.1 and U937 cell lines and low levels of expression in the T and B lymphoblastoid cell lines CEM and BJAB (Fig. 2C).


View larger version (68K):
[in this window]
[in a new window]
 
Fig. 2.   CARDINAL protein expression in human tissues and transformed cell lines. A, validation of anti-CARDINAL antibody. A rabbit polyclonal antibody against CARDINAL was generated and affinity-purified as described under "Experimental Procedures." HEK 293T cells were transfected with the indicated amounts of pcDNA3 empty vector or pcDNA3-CARDINAL, and lysates made 24 h later. Equal amounts of total protein (~50 µg) were then analyzed by immunoblotting for CARDINAL expression, or actin as a loading control, as indicated. B, CARDINAL protein expression in adult human tissues. Whole cells lysates (100 µg/lane) from the indicated human tissues were analyzed for CARDINAL expression by immunoblotting. Blots were stripped and re-probed for actin. C, CARDINAL protein expression in human tumor cell lines. Total protein lysates (50 µg/lane) were prepared from the indicated human cell lines and assessed for CARDINAL expression by immunoblot. Duplicate blots were probed for beta -actin as a loading control, as indicated.

CARDINAL Subcellular Distribution-- To explore the subcellular localization of CARDINAL, an N-terminally EGFP-tagged CARDINAL expression plasmid was transiently transfected into MCF-7 cells. CARDINAL exhibited a mainly diffuse cytoplasmic distribution pattern, with a fraction of CARDINAL expression also detectable within the nucleus (Fig. 3). No significant overlap between CARDINAL and Mitotracker staining was observed. A similar subcellular distribution pattern of CARDINAL expression was also observed in 293T and HeLa cells (data not shown).


View larger version (65K):
[in this window]
[in a new window]
 
Fig. 3.   CARDINAL subcellular distribution. An expression plasmid encoding EGFP-tagged CARDINAL was transfected into MCF-7 cells, as described under "Experimental Procedures." 18 h after transfection, cells were stained with Mitotracker/Hoechst 33342, followed by examination under confocal microscopy. CARDINAL expression is indicated in green, mitochondria appear red, and nuclei are stained blue.

CARDINAL Fails to Promote Apoptosis or NF-kappa B Activation-- As discussed in the Introduction, most CARD-containing proteins that have been described to date have been implicated in pathways that lead to activation of caspases (and consequent apoptosis), or activation of the NF-kappa B transcription factor. Thus, we explored whether CARDINAL could promote either apoptosis or NF-kappa B activation upon transient overexpression. Fig. 4A illustrates that, whereas transient overexpression of the well established pro-apoptotic proteins FADD, TRADD, Bax, or RIP resulted in extensive apoptosis of MCF-7 cells, overexpression of CARDINAL failed to promote apoptosis under the same conditions. Dose-response experiments performed over a wide range of pcDNA3-CARDINAL plasmid concentrations yielded similar results (data not shown).


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 4.   Assessment of apoptosis and NF-kappa B activation associated with CARDINAL overexpression. A, MCF-7 cells were transfected with pcDNA3 empty vector (800 ng), or the same amount of expression plasmids encoding CARDINAL, FADD, Bax, TRADD, or RIP as indicated, along with 50 ng of beta -galactosidase reporter plasmid (pCMVbeta ). 48 h after transfection, the percentage of beta -galactosidase-positive (blue) cells exhibiting apoptotic features was determined from a minimum of 300 cells/well. Results are representative of three separate experiments. B, using standard calcium phosphate precipitation, HEK293T cells were transfected either with 1 µg of empty vector or with 1 µg of plasmids encoding RIP, TRADD, DR5, RICK, alongside the indicated amounts of pcDNA3-CARDINAL plasmid. All wells also received 200 ng of pGL35Xkappa B-luc and 100 ng of pCMVbeta reporter plasmids and were normalized to the same amount of total DNA using pcDNA3 empty vector. 24 h after transfection, cell lysates were prepared and luciferase activities associated with activation of the NF-kappa B-driven luciferase reporter were measured, in triplicate, as described under "Experimental Procedures." Luciferase activity values were normalized to beta -galactosidase activity values to correct for variability in transfection efficiency between wells. Cell lysates prepared from CARDINAL-transfected cells were also assessed for CARDINAL expression by immunoblotting (inset). Results are representative of at least six separate experiments.

We next explored whether CARDINAL could promote activation of NF-kappa B. Expression plasmids encoding CARDINAL, RIP, TRADD, TRAIL-R2 (DR5), or RICK were transfected into HEK293T cells along with a luciferase reporter construct under the control of five tandemly repeated NF-kappa B binding elements. Using this reporter system, significant NF-kappa B activity was detected upon transfection with RIP, TRADD, TRAIL-R2, and RICK, as expected (Fig. 4B). However, CARDINAL failed to activate NF-kappa B at any of the plasmid concentrations tested, despite high levels of CARDINAL protein expression being readily detectable in these cells (Fig. 4B, inset).

CARDINAL Is an Inhibitor of Multiple Pathways to NF-kappa B Activation-- While investigating the ability of CARDINAL to activate NF-kappa B, we noticed that CARDINAL-transfected cells consistently produced NF-kappa B-driven luciferase reporter gene activity below the basal level of NF-kappa B activity seen with the empty vector control (data not shown). This suggested that CARDINAL may act to suppress rather than promote NF-kappa B activation. Thus, we co-transfected expression plasmids for CARDINAL along with a panel of established NF-kappa B activators (RIP, TRADD, DR4/TRAIL-R1, DR5/TRAIL-R2, Bcl10) to assess whether CARDINAL could suppress the ability of the latter to activate NF-kappa B. Fig. 5A illustrates that CARDINAL substantially attenuated NF-kappa B-dependent luciferase reporter gene activity associated with transient overexpression of RIP, TRADD, TRAIL-R1 (DR4), TRAIL-R2 (DR5), and Bcl10. CARDINAL also dose-dependently inhibited RICK-induced NF-kappa B activation (Fig. 5B). In contrast, CARDINAL did not influence activation of a luciferase reporter gene placed under the control of p53-responsive promoter elements, demonstrating that the effects of CARDINAL were specific to NF-kappa B (Fig. 5C).


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 5.   CARDINAL is an inhibitor of multiple pathways to NF-kappa B activation. A, left panel, HEK293T cells were transfected with 1 µg of expression plasmids encoding, RIP, TRADD, DR4, or DR5, along with 2 µg of either empty vector (black shading) or 2 µg of pcDNA3-CARDINAL (hatched shading). Right panel, HEK293T cells were transfected with 1 µg of an expression plasmid encoding Bcl10, along with 1 µg of either empty vector (black shading) or 1 µg of pcDNA3-CARDINAL (hatched shading). In both cases, all wells also received 100 ng of pGL35Xkappa B-luc and 50 ng of pCMVbeta reporter plasmids and were normalized to the same amount of total DNA using pcDNA3 empty vector. 24 h after transfection, cells were lysed and NF-kappa B-driven luciferase reporter activities were measured, in triplicate, as described under "Experimental Procedures." Luciferase activity values were normalized to beta -galactosidase activity values to correct for variability in transfection efficiency between wells. Results are representative of three separate experiments. B, HEK293T cells were transfected with 1 µg of RICK expression plasmid, along with the indicated amounts of pcDNA3-CARDINAL. All wells also received the pGL35Xkappa B-luc (100 ng) and pCMVbeta (50 ng) reporter plasmids. Luciferase assays were performed 24 h after transfection and normalized to correct for transfection efficiency as described above. Lysates were also assessed for CARDINAL expression by immunoblot using anti-CARDINAL rabbit polyclonal antibody (lower panel). C, CARDINAL does not inhibit transactivation of a p53-responsive luciferase reporter gene. HEK 293T cells were transfected with 500 ng of empty vector or 500 ng of a p53 expression plasmid, along with 1 µg of empty vector (black shading) or 1 µg or CARDINAL expression plasmid (hatched shading). All wells also received 100 ng of p53-luc and 50 ng of pCMVbeta reporter plasmids. 24 h after transfection, cells were lysed and p53-driven luciferase reporter activities were measured (in triplicate) and normalized to beta -galactosidase activity values. Results are representative of three separate experiments.

Inhibition of IL-1- and TNF-associated NF-kappa B Activity by CARDINAL-- We next explored whether CARDINAL could inhibit NF-kappa B activation associated with engagement of the IL-1 or TNF receptors with their natural ligands. Thus, HEK293T cells were transiently transfected with either empty vector (pcDNA3), pcDNA3-CARDINAL, or the poxvirus-derived caspase-inhibitor CrmA, along with a NF-kappa B-driven luciferase reporter plasmid. Transfected cells were incubated for 24 h to allow expression of the transfected genes, followed by stimulation with either recombinant IL-1beta or TNFalpha for 6 h. Fig. 6 shows that, whereas CrmA expression failed to block NF-kappa B activation associated with IL-1beta or TNFalpha -treatment as expected, CARDINAL substantially suppressed NF-kappa B activation in both contexts.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 6.   CARDINAL inhibits IL-1- and TNF-associated NF-kappa B activation. HEK293T cells were transfected with either pCDNA3 empty vector (2 µg) or the same amounts of pcDNA3-CARDINAL, or pcDNA3-CrmA expression plasmids, as indicated. All wells also received the pGL35Xkappa B-luc (100 ng) and pCMVbeta (50 ng) reporter plasmids. 24 h after transfection, cultures were stimulated for 6 h with 20 ng/ml IL-1 or TNF, or were left untreated as shown. Cells were then lysed and NF-kappa B activation assays performed as described under "Experimental Procedures."

Deletional Analysis of CARDINAL-- To explore the region within CARDINAL responsible for inhibition of NF-kappa B activation, we constructed EGFP-tagged versions of full-length CARDINAL, a deletion mutant lacking the C-terminal CARD motif (EGFP-CARDINAL-(1-320)), and a mutant lacking the N-terminal NAC/DEFCAP-homologous region (EGFP-CARDINAL-(321-431); Fig. 7A). As in previous experiments, neither EGFP-tagged CARDINAL nor its deletion mutants were capable of spontaneously activating the NF-kappa B-driven luciferase reporter plasmid (Fig. 7B, left panel).


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 7.   Deletional analysis of CARDINAL. A, schematic representation of EGFP epitope-tagged CARDINAL deletion mutants. The CARD region is shaded in black. B, HEK293T cells were transfected with either EGFP vector (2 µg), or the same amount of the indicated EGFP-tagged CARDINAL expression plasmids, as indicated. All wells also received the pGL35Xkappa B-luc (100 ng) and pCMVbeta (50 ng) reporter plasmids. 24 h after transfection, cultures were stimulated for 6 h with 20 ng/ml IL-1 or TNF, or were left untreated as shown. Cells were then lysed and NF-kappa B activation assays performed as described under "Experimental Procedures." C, expression of EGFP and EGFP-CARDINAL deletion mutants under the conditions described in panel B. Total cell lysates (50 µg/lane) were analyzed by immunoblot with an anti-GFP monoclonal antibody.

However, relative to the EGFP control, EGFP-tagged full-length CARDINAL potently inhibited NF-kappa B-dependent reporter gene activity associated with exposure of HEK293T cells to either recombinant IL-1beta or TNFalpha (Fig. 7B). This inhibition was eliminated by removal of the N-terminal region of CARDINAL (amino acids 1-320), as the EGFP-CARDINAL-(321-431) mutant encoding the CARD region failed to suppress NF-kappa B activation associated with IL-1beta or TNFalpha treatment (Fig. 7B). The failure of EGFP-CARDINAL-(321-431) to suppress IL-1- or TNF-associated NF-kappa B activation signals was not because of decreased expression levels of the latter, as this mutant was expressed at levels comparable with, or even higher than, that of the other EGFP-tagged constructs (Fig. 7C). Moreover, in keeping with a role for the N terminus of CARDINAL as the region responsible for the observed effects on NF-kappa B activation, the EGFP-CARDINAL-(1-320) mutant was as potent as full-length EGFP-CARDINAL in repressing IL-1beta - or TNFalpha -driven NF-kappa B reporter gene activity under the same conditions (Fig. 7B).

CARDINAL Interacts with IKKgamma (NEMO)-- Because CARDINAL could antagonise NF-kappa B activation associated with engagement of multiple independent receptor pathways (IL-1, TNF, TRAIL-R1/DR4, TRAIL-R2/DR5), we considered it likely that CARDINAL intervened in these pathways at their point of convergence, or beyond. Many studies have shown that activation of the IKK complex is a key convergence point in divergent signaling pathways that result in NF-kappa B activation (25-27). In addition, recent studies have demonstrated that both RIP and RICK promote NF-kappa B activation by direct binding to the regulatory subunit of the IKK complex, IKKgamma /NEMO (23, 28, 29). Because CARDINAL could antagonize NF-kappa B activation associated with transient overexpression of either RIP or RICK (Fig. 5, A and B), this suggested that CARDINAL may act at the level of IKKgamma /NEMO recruitment by RICK or RIP, or at a point downstream of this.

Thus, we asked whether CARDINAL could directly bind to IKKgamma , providing a means whereby this CARD protein could antagonize multiple independent NF-kappa B activation pathways. To explore this possibility, HEK293T cells were co-transfected with expression plasmids encoding IKKgamma , in combination with EGFP or EGFP-CARDINAL. 24 h after transfection, cell lysates were made and CARDINAL was immunoprecipitated using an anti-CARDINAL polyclonal antibody. Immune complexes were then probed for the presence of co-precipitated IKKgamma . Fig. 8A illustrates that IKKgamma was readily detectable in CARDINAL precipitates, suggesting that CARDINAL directly interacts with this subunit of the IKK complex. Additional co-immunoprecipitation experiments with the other components of the IKK signalsome (IKKalpha , IKKbeta ) revealed that CARDINAL selectively co-precipitated IKKgamma (Fig. 8B). Furthermore, co-immunoprecipitation experiments with CARDINAL and several CARD-containing caspases (caspase-1, caspase-2, caspase-4, caspase-5, and caspase-9) failed to find association between CARDINAL and the latter molecules (data not shown). The ability of CARDINAL to interact with IKKgamma /NEMO provides a molecular basis for the observed NF-kappa B inhibitory effects of CARDINAL. Thus, CARDINAL may compete with other CARD proteins, such as RICK and Bcl10, for recruitment of IKKgamma thereby antagonizing NF-kappa B activation in multiple independent signaling pathways.


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 8.   CARDINAL interacts with IKK-gamma (NEMO). A, HEK293T cells were transfected with 5 µg of T7 epitope-tagged IKKgamma , along with 5 µg of plasmids encoding EGFP or EGFP-CARDINAL, as indicated. 24 h after transfection, cells were lysed and CARDINAL was immunoprecipitated with anti-CARDINAL polyclonal antibody, followed by probing with horseradish peroxidase-linked anti-T7 monoclonal antibody (Novagen) or anti-GFP monoclonal antibody (CLONTECH), as shown. B, HEK293T cells were transfected with 5 µg of the indicated T7 epitope-tagged IKK expression plasmids, along with 5 µg of pcDNA3-CARDINAL, as indicated. 24 h after transfection, cells were lysed and CARDINAL was immunoprecipitated with anti-CARDINAL polyclonal antibody, followed by probing with anti-T7 or anti-CARDINAL antibodies, as shown. The asterisk represents immunoglobulin heavy chain; the arrow indicates T7-tagged IKKgamma .


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Here we report the identification of CARDINAL, a CARD-containing protein that exhibits potent NF-kappa B-inhibitory activity. CARDINAL was found to associate with IKKgamma but not with several CARD-containing caspases. Consistent with this, CARDINAL failed to promote apoptosis but was found to antagonize NF-kappa B activation signals initiated by a variety of receptors or their adaptors. During the preparation of this report, CARDINAL was also reported by Reed and colleagues as TUCAN (30). Although there is broad agreement on the domain structure, tissue distribution, and failure of TUCAN to promote apoptosis, Reed's group report that TUCAN can act as an antagonist of caspase-9 and can block apoptosis associated with transient overexpression of Bax or caspase-9/Apaf-1 (30). In contrast, our investigations along these lines failed to find a role for CARDINAL/TUCAN as an inhibitor of apoptosis, or an interaction partner for caspase-9 (data not shown). Rather, we have found that CARDINAL/TUCAN antagonizes NF-kappa B activation, a role that was not explored by Pathan et al. (30). Some of the disagreement between the two groups may relate to the expression systems/assays used. Clearly, further investigation of CARDINAL/TUCAN, particularly at constitutive protein levels, will be required to resolve these issues.

As outlined in the Introduction, many recent studies have implicated CARD-containing proteins as signaling components of pathways that result in NF-kappa B activation (see Ref. 22 for a recent review). The Bcl10 CARD protein appears to be a common convergence point for several recently described CARD proteins that activate NF-kappa B (16, 18, 19). Moreover, using BCL10-null mice, it has also been found that Bcl10 is essential for NF-kappa B activation associated with stimulation of the T or B cell receptors for antigen (20).

A different route to NF-kappa B activation appears to involve a distinct set of CARD proteins, which includes members of the Nod1/Apaf-1 family. Apaf-1 is a well established caspase-activating molecule that exhibits homology with the Caenorhabditis elegans caspase-activating protein CED-4 (31). Apaf-1 possesses an N-terminal CARD motif, a nucleotide-binding domain, and a domain rich in WD repeats that acts as a sensor for cellular damage through binding of cytosolic cytochrome c (9, 31). Upon binding of cytosolic cytochrome c that has escaped from mitochondria through cell stress/damage, Apaf-1 acts as an oligomerization and activation platform for caspase-9. Recently, two CARD-containing proteins with significant homology to Apaf-1 (Nod1/CARD4 and Nod2) have been described that, in contrast to Apaf-1, appear to be primarily involved in NF-kappa B activation through recruitment of the RICK kinase (17, 23). Because RICK has been shown to interact with IKKgamma , this suggests that aggregation of RICK by the Apaf-1/Nod1-like family members may result in NF-kappa B activation through downstream activation of the IKK complex via an induced proximity mechanism (23).

Strikingly, Nod1/CARD4 and Nod2 have recently been implicated as intracellular sensors for bacterial lipopolysaccharide, through binding of this conserved component of Gram-negative bacteria through their leucine-rich repeat regions (32). Furthermore, Nod1/CARD4 and Nod2 also share significant homology with plant disease resistance (R) proteins that also act as intracellular sensors of pathogen products. Thus, the Nod1/Apaf-1 family appear to be involved in host defense responses to different forms of cellular stress (bacterial infection, cell damage) where the outcome is either caspase activation and apoptosis (in the case of Apaf-1), or NF-kappa B activation and a pro-inflammatory response (in the case of Nod1/CARD4 and Nod2).

Given the emerging role for CARD-family proteins as signaling intermediaries in multiple pathways that result in NF-kappa B activation, CARDINAL may act to counteract some of the latter molecules to set a threshold for NF-kappa B activation. Alternatively, CARDINAL may play a role in limiting the duration of NF-kappa B activation, through competition with other proteins for IKKgamma /NEMO recruitment. Further work is clearly necessary to explore how CARDINAL expression/stability is regulated in response to pro-inflammatory stimuli and to determine the specific biological context(s) in which CARDINAL operates.

The significance of the extensive homology between the N terminus of CARDINAL and the C terminus of DEFCAP/NAC also remains unclear. DEFCAP/NAC is a member of the Apaf-1/Nod1 family of CARD/nucleotide binding domain proteins (33, 34). There is disagreement as to the specific binding partners of DEFCAP/NAC (caspase-2/caspase-9 versus Apaf-1) and whether this protein promotes caspase activation and apoptosis via direct or indirect means (33, 34). The domain structure of NAC/DEFCAP would strongly suggest that this protein is likely to act as a sensor for pathogen products, akin to Nod1/CARD4 and Nod2, although this remains to be determined. The latter possibility introduces a scenario where CARDINAL may act to antagonise signals routed through DEFCAP/NAC by competing for the same C-terminal binding partners of the latter.

Clearly, there are many interesting questions concerning CARDINAL function that require further investigation. In the present study, we have provided data to suggest that CARDINAL can antagonize NF-kappa B activation signals in diverse contexts. This represents a novel function for a CARD family protein and adds to the growing body of evidence that proteins containing CARD motifs play diverse roles within the overall context of host defense.

    ACKNOWLEDGEMENTS

We thank Drs. Emad Alnemri, Vishva Dixit, David Goeddel, Doug Green, Gabriel Nunez, Jurg Tschopp, and Henning Walczak for valuable reagents.

    FOOTNOTES

* This work was supported in part by Wellcome Trust Senior Fellowship Award in Biomedical Science 047580 and EU Grant QLG1-1999-00739 (to S. J. M. and M. M.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF405558.

§ Supported by Wellcome Trust Prize Studentship Award 055295.

|| To whom correspondence should be addressed. Tel.: 353-1-608-1289; Fax: 353-1-679-8558; E-mail: martinsj@tcd.ie.

Published, JBC Papers in Press, September 10, 2001, DOI 10.1074/jbc.M107373200

    ABBREVIATIONS

The abbreviations used are: CARD, caspase recruitment domain; DED, death effector domain; GST, glutathione S-transferase; GFP, green fluorescent protein; EGFP, enhanced green fluorescent protein; IL, interleukin; TNF, tumor necrosis factor; PBS, phosphate-buffered saline; IKK, Ikappa B kinase.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Hofmann, K., Bucher, P., and Tschopp, J. (1997) Trends Biochem. Sci. 22, 155-156[CrossRef][Medline] [Order article via Infotrieve]
2. Martin, S. J., and Green, D. R. (1995) Cell 82, 349-352[CrossRef][Medline] [Order article via Infotrieve]
3. Earnshaw, W. C., Martins, L. M., and Kaufmann, S. H. (1999) Annu. Rev. Biochem. 68, 383-424[CrossRef][Medline] [Order article via Infotrieve]
4. Nicholson, D. W. (1999) Cell Death Differ. 6, 1028-1042[CrossRef][Medline] [Order article via Infotrieve]
5. Slee, E. A., Adrain, C., and Martin, S. J. (1999) Cell Death Differ. 6, 1067-1074[CrossRef][Medline] [Order article via Infotrieve]
6. Slee, E. A., Adrain, C., and Martin, S. J. (2001) J. Biol. Chem. 276, 7320-7326[Abstract/Free Full Text]
7. Aravind, L., Dixit, V. M., and Koonin, E. V. (1999) Trends Biochem. Sci. 24, 47-53[CrossRef][Medline] [Order article via Infotrieve]
8. Kumar, S., and Colussi, P. A. (1999) Trends Biochem. Sci. 24, 1-4[CrossRef][Medline] [Order article via Infotrieve]
9. Adrain, C., and Martin, S. J. (2001) Trends Biochem. Sci. 26, 390-397[CrossRef][Medline] [Order article via Infotrieve]
10. Salvesen, G. S., and Dixit, V. M. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 10964-10967[Abstract/Free Full Text]
11. Willis, T. G., Jadayel, D. M., Du, M. Q., Peng, H., Perry, A. R., Abdul-Rauf, M., Price, H., Karran, L., Majekodunmi, O., Wlodarska, I., Pan, L., Crook, T., Hamoudi, R., Isaacson, P. G., and Dyer, M. J. (1999) Cell 96, 35-45[CrossRef][Medline] [Order article via Infotrieve]
12. Koseki, T., Inohara, N., Chen, S., Carrio, R., Merino, J., Hottiger, M. O., Nabel, G. J., and Nunez, G. (1999) J. Biol. Chem. 274, 9955-9961[Abstract/Free Full Text]
13. Srinivasula, S. M., Ahmad, M., Lin, J. H., Poyet, J. L., Fernandes-Alnemri, T., Tsichlis, P. N., and Alnemri, E. S. (1999) J. Biol. Chem. 274, 17946-17954[Abstract/Free Full Text]
14. Bertin, J., Nir, W. J., Fischer, C. M., Tayber, O. V., Errada, P. R., Grant, J. R., Keilty, J. J., Gosselin, M. L., Robison, K. E., Wong, G. H., Glucksmann, M. A., and DiStefano, P. S. (1999) J. Biol. Chem. 274, 12955-12958[Abstract/Free Full Text]
15. Inohara, N., Koseki, T., del Peso, L., Hu, Y., Yee, C., Chen, S., Carrio, R., Merino, J., Liu, D., Ni, J., and Nunez, G. (1999) J. Biol. Chem. 274, 14560-14567[Abstract/Free Full Text]
16. Bertin, J., Guo, Y., Wang, L., Srinivasula, S. M., Jacobson, M. D., Poyet, J. L., Merriam, S., Du, M. Q., Dyer, M. J., Robison, K. E., DiStefano, P. S., and Alnemri, E. S. (2000) J. Biol. Chem. 275, 41082-41086[Abstract/Free Full Text]
17. Ogura, Y., Inohara, N., Benito, A., Chen, F. F., Yamaoka, S., and Nunez, G. (2001) J. Biol. Chem. 276, 4812-4818[Abstract/Free Full Text]
18. Wang, L., Guo, Y., Huang, W. J., Ke, X., Poyet, J. L., Manji, G. A., Merriam, S., Glucksmann, M. A., DiStefano, P. S., Alnemri, E. S., and Bertin, J. (2001) J. Biol. Chem. 276, 21405-21409[Abstract/Free Full Text]
19. Bertin, J., Wang, L., Guo, Y., Jacobson, M. D., Poyet, J. L., Srinivasula, S. M., Merriam, S., DiStefano, P. S., and Alnemri, E. S. (2001) J. Biol. Chem. 276, 11877-11882[Abstract/Free Full Text]
20. Ruland, J., Duncan, G. S., Elia, A., del Barco Barrantes, I., Nguyen, L., Plyte, S., Millar, D. G., Bouchard, D., Wakeham, A., Ohashi, P. S., and Mak, T. W. (2001) Cell 104, 33-42[CrossRef][Medline] [Order article via Infotrieve]
21. Poyet, J. L., Srinivasula, S. M., and Alnemri, E. S. (2001) J. Biol. Chem. 276, 3183-3187[Abstract/Free Full Text]
22. Martin, S. J. (2001) Trends Cell Biol. 11, 188-189[CrossRef][Medline] [Order article via Infotrieve]
23. Inohara, N., Koseki, T., Lin, J., del Peso, L., Lucas, P. C., Chen, F. F., Ogura, Y., and Nunez, G. (2000) J. Biol. Chem. 275, 27823-27831[Abstract/Free Full Text]
24. Adrain, C., Slee, E. A., Harte, M. T., and Martin, S. J. (1999) J. Biol. Chem. 274, 20855-20860[Abstract/Free Full Text]
25. Yamaoka, S., Courtois, G., Bessia, C., Whiteside, S. T., Weil, R., Agou, F., Kirk, H. E., Kay, R. J., and Israel, A. (1998) Cell 93, 1231-1240[CrossRef][Medline] [Order article via Infotrieve]
26. Rothwarf, D. M., Zandi, E., Natoli, G., and Karin, M. (1998) Nature 395, 297-300[CrossRef][Medline] [Order article via Infotrieve]
27. Rudolph, D., Yeh, W. C., Wakeham, A., Rudolph, B., Nallainathan, D., Potter, J., Elia, A. J., and Mak, T. W. (2000) Genes Dev. 14, 854-862[Abstract/Free Full Text]
28. Poyet, J. L., Srinivasula, S. M., Lin, J. H., Fernandes-Alnemri, T., Yamaoka, S., Tsichlis, P. N., and Alnemri, E. S. (2000) J. Biol. Chem. 275, 37966-37977[Abstract/Free Full Text]
29. Zhang, S. Q., Kovalenko, A., Cantarella, G., and Wallach, D. (2000) Immunity 12, 301-311[CrossRef][Medline] [Order article via Infotrieve]
30. Pathan, N., Marusawa, H., Krajewska, M., Matsuzawa, Si S., Kim, H., Okada, K., Torii, S., Kitada, S., Krajewski, S., Welsh, K., Pio, F., Godzik, A., and Reed, J. C. (2001) J. Biol. Chem. 276, 32220-32229[Abstract/Free Full Text]
31. Zou, H., Henzel, W. J., Liu, X., Lutschg, A., and Wang, X. (1997) Cell. 90, 405-413[CrossRef][Medline] [Order article via Infotrieve]
32. Inohara, N., Ogura, Y., Chen, F. F., Muto, A., and Nunez, G. (2001) J. Biol. Chem. 276, 2551-2554[Abstract/Free Full Text]
33. Chu, Z. L., Pio, F., Xie, Z., Welsh, K., Krajewska, M., Krajewski, S., Godzik, A., and Reed, J. C. (2001) J. Biol. Chem. 276, 9239-9245[Abstract/Free Full Text]
34. Hlaing, T., Guo, R. F., Dilley, K. A., Loussia, J. M., Morrish, T. A., Shi, M. M., Vincenz, C., and Ward, P. A. (2001) J. Biol. Chem. 276, 9230-9238[Abstract/Free Full Text]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Leukoc. Biol.Home page
J. M. Wilmanski, T. Petnicki-Ocwieja, and K. S. Kobayashi
NLR proteins: integral members of innate immunity and mediators of inflammatory diseases
J. Leukoc. Biol., January 1, 2008; 83(1): 13 - 30.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Fontalba, V. Martinez-Taboada, O. Gutierrez, C. Pipaon, N. Benito, A. Balsa, R. Blanco, and J. L. Fernandez-Luna
Deficiency of the NF-{kappa}B Inhibitor Caspase Activating and Recruitment Domain 8 in Patients with Rheumatoid Arthritis Is Associated with Disease Severity
J. Immunol., October 1, 2007; 179(7): 4867 - 4873.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
Y. Wang, T. Chen, C. Han, D. He, H. Liu, H. An, Z. Cai, and X. Cao
Lysosome-associated small Rab GTPase Rab7b negatively regulates TLR4 signaling in macrophages by promoting lysosomal degradation of TLR4
Blood, August 1, 2007; 110(3): 962 - 971.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
H. An, H. Xu, M. Zhang, J. Zhou, T. Feng, C. Qian, R. Qi, and X. Cao
Src homology 2 domain-containing inositol-5-phosphatase 1 (SHIP1) negatively regulates TLR4-mediated LPS response primarily through a phosphatase activity- and PI-3K-independent mechanism
Blood, June 15, 2005; 105(12): 4685 - 4692.
[Abstract] [Full Text] [PDF]


Home page
Sci SignalHome page
J. C. Reed, K. S. Doctor, and A. Godzik
The Domains of Apoptosis: A Genomics Perspective
Sci. Signal., June 29, 2004; 2004(239): re9 - re9.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
S. S. Sathe, N. Sizemore, X. Li, K. Vithalani, M. Commane, S. M. Swiatkowski, and G. R. Stark
Mutant human cells with constitutive activation of NF-{kappa}B
PNAS, January 6, 2004; 101(1): 192 - 197.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
W. O'Connor Jr, J. A. Harton, X. Zhu, M. W. Linhoff, and J. P.-Y. Ting
Cutting Edge: CIAS1/Cryopyrin/PYPAF1/NALP3/ CATERPILLER 1.1 Is an Inducible Inflammatory Mediator with NF-{k